三阴性乳腺癌治疗的免疫疗法
Immunotherapy for the Treatment of Triple-Negative Breast Cancer.
作者信息
Tolaney Sara M, Shaw Lindsay
机构信息
Dana-Farber Cancer Institute, Boston, Massachusetts.
出版信息
J Adv Pract Oncol. 2022 Apr;13(3):298-301. doi: 10.6004/jadpro.2022.13.3.23. Epub 2022 May 23.
Abstract
At JADPRO Live Virtual 2021, Sara M. Tolaney, MD, MPH, and Lindsay Shaw, ANP-BC, AOCNP®, presented on recent clinical trial data for approved immune checkpoint inhibitors and antibody-drug conjugates, and their implications in the current treatment landscape, for metastatic triple-negative breast cancer. Dr. Tolaney and Ms. Shaw also discussed principles of monitoring and managing adverse events associated with immunotherapies.
摘要
在2021年JADPRO现场虚拟会议上，医学博士、公共卫生硕士萨拉·M·托拉尼和高级执业护士、认证肿瘤学高级执业护士林赛·肖介绍了已获批的免疫检查点抑制剂和抗体药物偶联物的近期临床试验数据，以及它们在转移性三阴性乳腺癌当前治疗格局中的意义。托拉尼博士和肖女士还讨论了监测和管理与免疫疗法相关不良事件的原则。
相似文献
1
Immunotherapy for the Treatment of Triple-Negative Breast Cancer.三阴性乳腺癌治疗的免疫疗法
J Adv Pract Oncol. 2022 Apr;13(3):298-301. doi: 10.6004/jadpro.2022.13.3.23. Epub 2022 May 23.
2
Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments.三阴性乳腺癌专家见解：为下一波治疗做准备
J Adv Pract Oncol. 2020 Apr;11(3):266-270. doi: 10.6004/jadpro.2020.11.3.10. Epub 2020 Apr 1.
3
[Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].[三阴性转移性乳腺癌的近期治疗趋势：PARP抑制剂、免疫疗法和抗体药物偶联物]
Bull Cancer. 2021 Jan;108(1):67-79. doi: 10.1016/j.bulcan.2020.11.007. Epub 2021 Jan 6.
4
Infrequent Offenders: Neuroendocrine Tumors and Cancers of the Appendix, Gallbladder, and Bile Duct.罕见肿瘤：阑尾、胆囊和胆管的神经内分泌肿瘤及癌症
J Adv Pract Oncol. 2021 Apr;12(3):315-318. doi: 10.6004/jadpro.2021.12.3.20. Epub 2021 Apr 1.
5
Updates in Cholangiocarcinoma.胆管癌的最新进展
J Adv Pract Oncol. 2022 Apr;13(3):320-323. doi: 10.6004/jadpro.2022.13.3.28. Epub 2022 May 23.
6
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.乳腺癌的新兴联合免疫治疗策略：双重免疫检查点调节、抗体药物偶联物和双特异性抗体。
Breast Cancer Res Treat. 2022 Jan;191(2):291-302. doi: 10.1007/s10549-021-06423-0. Epub 2021 Oct 30.
7
Immune Checkpoint Inhibitor-Based Therapy as a Backbone in Cancer Treatment.基于免疫检查点抑制剂的疗法作为癌症治疗的支柱
J Adv Pract Oncol. 2020 Apr;11(3):231-233. doi: 10.6004/jadpro.2020.11.3.3. Epub 2020 Apr 1.
8
Developments in Hepatocellular Cancer Treatment.肝细胞癌治疗的进展
J Adv Pract Oncol. 2021 Apr;12(3):310-314. doi: 10.6004/jadpro.2021.12.3.19. Epub 2021 Apr 1.
9
Diagnosis and Treatment of AL and ATTR Amyloidosis.AL型和ATTR型淀粉样变性的诊断与治疗
J Adv Pract Oncol. 2021 Apr;12(3):329-332. doi: 10.6004/jadpro.2021.12.3.24. Epub 2021 Apr 1.
10
The Advanced Practice Role in Clinical Trials: Past, Present, and Future.临床试验中的高级实践角色：过去、现在与未来。
J Adv Pract Oncol. 2022 Apr;13(3):217-220. doi: 10.6004/jadpro.2022.13.3.7. Epub 2022 May 23.
本文引用的文献
1
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
2
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.奥拉帕利辅助治疗 - 或 - 突变型乳腺癌患者。
N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.
3
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan 治疗转移性三阴性乳腺癌。
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
4
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
5
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.阿替利珠单抗联合白蛋白紫杉醇治疗晚期三阴性乳腺癌。
N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.
Zotero 插件